Clovis Oncology ( (CLVS) ) won approval today for its new ovarian cancer drug known as Rubraca. According to the FDA, the drug is approved to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whos tumors have a specific gene mutation known as BRCA. The agency approved Rubraca under its accelerated approval program. The National Cancer Institute estimates that more than 22,000 women will be diagnosed with ovarian cancer in 2016 and an estimated 14,000 will die of this disease. Approximately 15 to 20 percent of patients with ovarian cancer have a BRCA gene mutation.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.